# Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients

> **NCT02079896** · PHASE1,PHASE2 · COMPLETED · sponsor: **TME Pharma AG** · enrollment: 33 (actual)

## Conditions studied

- Anemia
- End Stage Renal Disease

## Interventions

- **DRUG:** Lexaptepid pegol (NOX-H94)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02079896
- **Lead sponsor:** TME Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2015-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079896, "Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02079896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*